On June 18, 2025, the FDA approved lenacapavir, a long-acting medication that could reshape the global fight against HIV, one of the world’s most persistent pandemics.
Approved under the brand name Yeztugo, lenacapavir is the first and only pre-exposure prophylaxis (PrEP) option that requires just two doses per year. For millions of people who struggle with the demands of taking a pill every day due to stigma, forgetfulness, or limited access to healthcare, this offers more
